{"id":"W2887412253","doi":"10.1016/s0140-6736(18)31713-6","title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":662,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Dermira; Genentech; Celgene; AbbVie; GlaxoSmithKline Australia; Bristol-Myers Squibb; Amgen; Boehringer Ingelheim","keywords":"Medicine; Ustekinumab; Placebo; Psoriasis Area and Severity Index; Internal medicine; Psoriasis; Clinical trial; Randomization; Randomized controlled trial; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00363189,0.001231134,0.003357812,0.0004079811,0.0004108593,0.001233668,0.0009203912,0.002435458,0.002612107],"category_scores_gemma":[0.002430107,0.0007056655,0.003265024,0.000352741,0.001287493,0.001023238,0.0003532109,0.003282111,0.000625027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006551339,"about_ca_system_score_gemma":0.0007292493,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006099063,"about_ca_topic_score_gemma":0.001260611,"domain_scores_codex":[0.9989636,0.0004858751,0.0001084195,0.0001692191,0.0001414872,0.0001315005],"domain_scores_gemma":[0.9985532,0.0005708056,0.0003793415,0.00009579829,0.00009276885,0.0003081144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9211179,0.003821422,0.001847841,0.002570732,0.003249578,0.00008482602,0.0001134726,0.0003399384,0.007599453,0.0001480178,0.001366546,0.05774019],"study_design_scores_gemma":[0.9162026,0.07184571,0.00666052,0.0001086454,0.002065852,0.0001803068,0.00003784655,0.0002580376,0.001101915,0.0002504931,0.001255801,0.00003228939],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9438567,0.04879146,0.000630446,0.001104486,0.0005907238,0.001257324,0.0009855554,0.0001401108,0.00264328],"genre_scores_gemma":[0.9814737,0.01224748,0.001105067,0.001389287,0.0006099399,0.0006880263,0.001140868,0.00002430703,0.001321302],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00363189,"threshold_uncertainty_score":0.01920748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05257706308536371,"score_gpt":0.3200678952590045,"score_spread":0.2674908321736408,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}